Source disclosure: February 10, 2026
KOBAYASHI PHARMACEUTICAL CO.,LTD. [4967.T]
TOKYO, Feb 10 (Pulse News Wire) – Kobayashi Pharmaceutical CO.,LTD. (4967.T) announced its opposition to shareholder proposals set to be discussed at its upcoming annual general meeting scheduled for March 27, 2026.
The proposals, submitted by Oasis Japan Strategic Fund Ltd., include appointing an additional auditor, amending certain provisions of the articles of incorporation, and adding clauses related to monthly reporting to outside directors and quality management. The board of directors concluded after thorough deliberation that none of the proposed changes align with their strategic goals for corporate governance reform. Specifically, the company opposes the appointment of an additional auditor due to recent enhancements in its internal control systems and ongoing efforts to strengthen oversight mechanisms through the transition to a committee-based audit system.
Additionally, the board believes that limiting the role of the board chairman to external directors would undermine effective supervision and operational flexibility. Regarding the proposal to mandate monthly reports to outside directors, the company argues that such requirements should remain flexible within the operational framework rather than being codified in the articles of incorporation. Similarly, the suggestion to incorporate detailed quality and safety management clauses into the articles is seen as unnecessary, given the company's existing robust measures and continuous improvement initiatives.
In conclusion, Kobayashi Pharmaceutical maintains its stance against all four proposals, emphasizing its commitment to enhancing corporate governance and ensuring comprehensive oversight without compromising operational efficiency.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing